Antiepileptic drug treatment before and after selective amygdalohippocampectomy.
Retrospectively, we analyzed pre and postoperative (po) AED treatment in relation to long-term annual seizure outcome in the Zurich selective amygdalohippocampectomy (AHE) series. In 376 patients (hippocampal sclerosis ("HS"), n:185; other lesions ("lesional"), n:191) with a follow-up of more than 1 year, in the last available outcome (lao), 60% were seizure- and aura-free (ILAE Class 1). During the year prior to surgery, in the "HS" group a mean of 2.3 +/- 0.8 AEDs were taken. The percentage of patients without AEDs increases to 36.1% in the po years 1-5 (po year 5: "HS" (n:133) 27.8%; "lesional" (n:111) 45.9%). In po years 7-11 this percentage is between 40 and 43% (po year 10: "HS" (n:75) 29.3%; "lesional" (n:65) 55.4%). In the ILAE Class 1a, at po year 5 63/85 (74.1%) patients have discontinued AED intake. At lao 36.2% of patients were off AEDs and additional 18.9% had a "substantial" reduction (i.e. from polytherapy to monotherapy, or a reduction of the existing monotherapy by at least 66% compared to the year before AHE). The relapse rate is similar for patients who were free of disabling seizures (a) for > or =1 year and without AEDs (17.1%), (b) immediately after surgery with or without AEDs (18.4%), and (c) had a "substantial" AED reduction over the entire follow-up period (18.9%). The rate of re-gained full seizure control, however, is significantly better for group (b) compared to (c) (77% versus 53%). 10.9% of patients showed the "running down phenomenon," i.e. had seizures during the first po year, but then became seizure-free for 1 or more years. The percentage of patients free of "disabling" seizures, who did not follow the medical advice to discontinue/reduce AEDs, is about 30% after the 10th po year. In the 15th po year this figure is 4.2 times higher for "HS" versus "lesional" patients. We conclude that the time of discontinuation of AEDs after AHE should be tailored based on the results of the presurgical evaluation, the early po seizure outcome, the histopathological findings, the intraoperative ECoG findings and the po EEG. In an optimal constellation, "substantial" AED reduction with the goal of a monotherapy can be advised 1 year and discontinuation 2 years after surgery.
Wieser
Heinz-Gregor
HG
Department of Neurology, University Hospital Zurich, University of Zürich, Frauenklinikstrasse 26, CH-8091 Zürich, Switzerland. hgwepi@neurol.unizh.ch
Häne
Adrian
A
D000679:Amygdala / Q000601:surgery*; D000927:Anticonvulsants / Q000627:therapeutic use*; D004338:Drug Combinations; D004827:Epilepsy / Q000188:drug therapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006624:Hippocampus / Q000601:surgery*; D006801:Humans; D008297:Male; D019635:Neurosurgical Procedures; D018579:Patient Selection; D011446:Prospective Studies; D012008:Recurrence; D012189:Retrospective Studies; D012640:Seizures / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome
D000927:Anticonvulsants; D004338:Drug Combinations